Abbott Laboratories
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1944-01-01
- Employees
- 114K
- Market Cap
- -
- Website
- http://www.abbott.com
- Introduction
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
15
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
News
Senseonics Secures $75 Million in Funding to Accelerate Eversense 365 CGM Launch
Senseonics Holdings has initiated a $50 million public offering of common stock, with Abbott Laboratories committing an additional $25 million through a concurrent private placement.
FDA Launches 'Operation Stork Speed' to Modernize Infant Formula Safety and Nutrition Standards
The FDA and HHS have initiated 'Operation Stork Speed,' the first comprehensive review of infant formula nutritional standards since 1998, seeking public input through September 2025.
FDA Approves Abbott's Coronary IVL System Trial for Treating Calcified Coronary Artery Disease
Abbott Laboratories has received FDA approval for an Investigational Device Exemption to evaluate its Coronary Intravascular Lithotripsy System in patients with severely calcified coronary artery disease.
New Report Reveals Critical Insights into Clinical-Stage Pharma Partnerships from 2020-2025
A comprehensive new industry report analyzes over 1,670 clinical-stage partnering agreements in pharma and biotech from 2020-2025, providing unprecedented access to deal structures and financial terms.
Abbott's FreeStyle Libre CGM Systems Receive First-Ever Approval for Use During Medical Imaging as Semaglutide Supply Stabilizes
• Abbott's FreeStyle Libre 2 and 3 become the first patient-applied CGM systems approved for use during medical imaging procedures, marking a significant advancement in diabetes care management. • All doses of semaglutide (Ozempic, Wegovy) are now fully available in the market again, according to the FDA's drug shortage database, resolving previous supply constraints. • Bariatric surgeries have decreased by 26% from 2022 to 2023, correlating with increased prescriptions for GLP-1 receptor agonists, indicating a shift in obesity treatment approaches.